

OptiPrep™ Mini-Review MV08

Purification and analysis of parvoviruses

- ◆ OptiPrep™ is a sterile 60% (w/v) solution of iodixanol in water, density = 1.32 g/ml
- ◆ This short Mini-Review provides a bibliography of all those papers reporting the use of OptiPrep™ in the purification and analysis of parvoviruses.
- ◆ The gradient protocol for the purification of isolation of parvoviruses (Application Sheet V15) may be accessed from the OptiPrep™ Applications flash-drive or from the following website: www.axis-shield-density-gradient-media.com, click on “Methodology” then “Viruses” to open up the Virus Index. Other OptiPrep™ Application Sheets on the preparation and harvesting of gradients may also be accessed from the top of the Index.
- ◆ The references are divided alphabetically into “**Virus type**” and where appropriate, into “**Research topic**” sections.
- ◆ All references are listed alphabetically according to **First Author**

1. *Densovirinae* (*Penaeus stylirostris*)

Kaufmann, B., Bowman, V.D., Li, Y., Szelei, J., Waddell, P.J., Tijssen, P. and Rossmann, M.G. (2010) *Structure of Penaeus stylirostris densovirus, a shrimp pathogen* J. Virol., **84**, 11289-11296

2. Minute virus

Cotmore, S.F. and Tattersall, P. (2005) *Encapsidation of minute virus of mice DNA: Aspects of the translocation mechanism revealed by the structure of partially packaged genomes* Virology, **336**, 100-112

Cotmore, S.F., Hafenstein, S. and Tattersall, P. (2010) *Depletion of virion-associated divalent cations induces parvovirus minute virus of mice to eject its genome in a 3'-to-5' direction from an otherwise intact viral particle* J. Virol., **84**, 1945-1956

Cotmore, S.F. and Tattersall, P. (2012) *Mutations at the base of the icosahedral five-fold cylinders of minute virus of mice induce 3'-to-5' genome uncoating and critically impair entry functions* J. Virol., **86**, 69-80

D'Abramo Jr., A.M., Ali, A.A., Wang, F., Cotmore, S.F. and Tattersall, P. (2005) *Host range mutants of minute virus of mice with a single VP2 amino acid change require additional silent mutations that regulate NS2 accumulation* Virology, **340**, 143-154

Farr, G.A., Cotmore, S.F. and Tattersall, P. (2006) *VP2 cleavage and the leucine ring at the base of the fivefold cylinder control pH-dependent externalization of both the VP1 N terminus and the genome of minute virus of mice* J. Virol., **80**, 161-171

Grekova, S., Zawatzky, R., Hörlein, R., Cziepluch, C., Minckberg, M., Davis, C., Rommelaere, J. and Daeffler, L. (2010) *Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism* J. Virol., **84**, 516-531

Grekova, S.P., Raykov, Z., Zawatzky, R., Rommelaere, J. and Koch, U. (2012) *Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection* Cancer Gene Ther., **19**, 468-475

Halder, S., Cotmore, S., Heimburg-Molinaro, J., Smith, D.F., Cummings, R.D., Chen, X., Trollope, A.J., North, S.J., Haslam, S.M., Dell, A., Tattersall, P., McKenna, R. and Agbandje-McKenna, M. (2014) *Profiling of glycan receptors for minute virus of mice in permissive cell lines towards understanding the mechanism of cell recognition* PLoS One, **9**: e86909

Lang, S.I., Boelz, S., Stroh-Dege, A.Y., Rommelaere, J., Dinsart, C. and Cornelis, J.J. (2005) *The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different* J. Virol., **79**, 289-298

Lang, S.I., Giese, N.A., Rommelaere, J., Dinsart, C. and Cornelis, J.J. (2006) *Humoral immune responses against minute virus of mice vectors* J. Gene Med., **8**, 1141-1150

Li, L., Cotmore, S.F. and Tattersall, P. (2012) *Maintenance of the flip sequence orientation of the ears in the parvoviral left-end hairpin is a nonessential consequence of the critical asymmetry in the hairpin stem* J. Virol., **86**, 12187-12197

Li, L., Cotmore, S.F. and Tattersall, P. (2013) *Parvoviral left-end hairpin ears are essential during infection for establishing a functional intranuclear transcription template and for efficient progeny genome encapsidation* J. Virol., **87**, 10501-10514

- Meira, C.**, Mincberga, M., Rostovskya, I., Tala, S., Vollmers, E.M., Levia, A., Tattersall, P. and Davis, C. (2017) *The MVMP P4 promoter is a host cell-type range determinant in vivo* Virology, **506**, 141–151
- Paglino, J.**, Burnett, E. and Tattershall, P. (2007) *Exploring the contribution of distal P4 promoter elements to the oncosensitivity of minute virus of mice* Virology, **361**, 174-184
- Plevka, P.**, Hafenstein, S., Li, L., D'Abramo, A., Cotmore, S.F., Rossmann, M.G. and Tattersall, P. (2011) *Structure of a packaging-defective mutant of minute virus of mice indicates that the genome is packaged via a pore at a 5-Fold axis* J. Virol., **85**, 4822–4827
- Rostovsky, I.** and Davis, C. (2015) *Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice* J. Virol., **89**, 2182-2191
- Ruiz, Z.**, Mihaylov, I.S., Cotmore, S.F. and Tattersall, P. (2011) *Recruitment of DNA replication and damage response proteins to viral replication centers during infection with NS2 mutants of Minute Virus of Mice (MVM)* Virology **410**, 375–384
- Subramanian, S.**, Organtini, L.J., Grossman, A., Domeier, P.P., Cifuentes, J.O., Makhov, A.M., Conway, J.F., D'Abramo, A., Cotmore, S.F., Tattersall, P. and Hafenstein, S. (2017) *Cryo-EM maps reveal five-fold channel structures and their modification by gatekeeper mutations in the parvovirus minute virus of mice (MVM) capsid* Virology, **510**, 216–223
- Vollmers, E.M.** and Tattersall, P. (2013) *Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses* Virology, **446**, 37–48

3. Parvovirinae

3.1 Adeovirus-parvovirus chimeras

- El-Andaloussi, N.**, Bonifati, S., Kaufmann, J.K., Mailly, L., Daeffler, L., Deryckère, F., Nettelbeck, D.M., Rommelaere, J. and Marchini, A. (2012) *Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential* J. Virol., **86**, 10418-10431

3.2 Capsid genes and proteins

- Allaume, X.**, El-Andaloussi, N., Leuchs, B., Bonifati, S., Kulkarni, A., Marttila, T., Kaufmann, J.K., Nettelbeck, D.M., Kleinschmidt, J., Rommelaere, J. and Marchini, A. (2012) *Retargeting of rat parvovirus H-IPV to cancer cells through genetic engineering of the viral capsid* J. Virol., **86**, 3452–3465
- Bloom, M.E.**, Best, S.M., Hayes, S.F., Wells, R.D., Wolfenbarger, J.B., McKenna, R. and Agbandje-McKenna, M. (2001) *Identification of Aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation* J. Virol., **75**, 11116-11127
- Farr, G.A.** and Tattersall, P.A. (2004) *A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection* Virology, **323**, 243-256
- Farr, G.A.**, Zhang, L-G. and Tattersall, P. (2005) *Parvoviral virions deploy a capsid-tetramer lipolytic enzyme to breach the endosomal membrane during cell entry* Proc. Natl. Acad. Sci. USA, **102**, 17148-17153
- Krüger, L.**, Eskerski, H., Dinsart, C., Cornelis, J., Rommelaere, J., Haberkorn, H. and Kleinschmidt, J.A. (2008) *Augmented transgene expression in transformed cells using a parvoviral hybrid vector* Cancer Gene Ther., **15**, 252-267
- Maxwell, I.H.**, Terrell, K.L. and Maxwell, F. (2002) *Autonomous parvovirus vectors* Methods, **28**, 168-181
- Nelson, C.D.S.**, Minkinen, E., Bergkvist, M., Hoelzer, K., Fisher, M., Bothner, B. and Parrish, C.R. (2008) *Detecting small changes and additional peptides in the canine parvovirus capsid structure* J. Virol., **82**, 10397-10407
- Wrzesinski, C.**, Tesfay, L., Salome, N., Jauniaux, J-C., Rommelaere, J., Cornelis, J. and Dinsart, C. (2003) *Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells* J. Virol., **77**, 3851-3858

3.3 Carcinoma cell killing

- Angelova, A.L.**, Grekova, S.P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., Aprahamian, M., Bour, G., Rüffer, S., Cziepluch, C., Daeffler, L., Rommelaere, J., Werner, J., Raykov, Z. and Giese, N.A. (2014) *Complementary induction of immunogenic cell death by oncolytic parvovirus H-IPV and gemcitabine in pancreatic cancer* J. Virol., **88**, 5263–5276
- Bhat, R.** and Rommelaere, J. (2013) *NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells* BMC Cancer, **13**: 367

3.4 Cell, export from

- Li, J.** and Murtaugh, M.P. (2015) *Functional analysis of porcine reproductive and respiratory syndrome virus N-glycans in infection of permissive cells* Virology, **477**, 82–88

Weiss, N., Stroh-Dege, A., Rommelaere, J., Dinsart, C. and Salomé, N. (2012) *Infectivity of progeny virions H-IPV efficiently stimulates export and protein-coding sequence of parvovirus* J. Virol., **86**, 7554-7564

3.5 Cytokine/chemokine delivery

Dempe, S., Lavie, M., Struyf, S., Bhat, R., Verbeke, H., Paschek, S., Berghmans, N., Geibig, R., Rommelaere, J., Van Damme, J. and Dinsart, C. (2012) *Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment* Cancer Immunol. Immunother., **61**, 2113–2123

3.6 Cytotoxicity

Hristov, G., Krämer, M., Li, J., El-Andaloussi, N., Mora, R., Daeffler, L., Zentgraf, H., Rommelaere, J. and Marchini, A. (2010) *Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species* J. Virol., **84**, 5909-5922

Lacroix, J., Leuchs, B., Li, J., Hristov, G., Deubzer, H.E., Kulozik, A.E., Rommelaere, J., Schlehofer, J.R. and Witt, O. (2010) *Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells* Int. J. Cancer, **127**, 1230–1239

3.7 Drug delivery

Kiprianova, I., Thomas, N., Ayache, A., Fischer, M., Leuchs, B., Klein, M., Rommelaere, J. and Schlehofer, J.R. (2011) *Regression of glioma in rat models by intranasal application of parvovirus H-1* Clin. Cancer Res., **17**, 5333–5342

3.8 Gene therapy

Abschuetz, A., Kehl, T., Geibig, R., Leuchs, B., Rommelaere, J. and Régnier-Vigouroux, A. (2006) *Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells* Cell Tissue Res., **325**, 423-436

Allaume, X., El-Andaloussi, N., Leuchs, B., Bonifati, S., Kulkarni, A., Marttila, T., Kaufmann, J.K., Nettelbeck, D.M., Kleinschmidt, J., Rommelaere, J. and Marchini, A. (2012) *Retargeting of rat parvovirus H-IPV to cancer cells through genetic engineering of the viral capsid* J. Virol., **86**, 3452–3465

Angelova, A.L., Aprahamian, M., Grekova, S.P., Hajri, A., Leuchs, B., Giese, N.A., Dinsart, C., Herrmann, A., Balboni, G., Rommelaere, J. and Raykov, Z. (2009) *Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-IPV* Clin. Cancer Res., 2009; **15**, 511-519

Angelova, A.L., Aprahamian, M., Balboni, G., Delecluse, H-J., Feederle, R., Kiprianova, I., Grekova, S.P., Galabov, A.S., Witzens-Harig, M., Ho, A.D., Rommelaere, J. and Raykov, Z. (2009) *Oncolytic rat parvovirus H-IPV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies* Mol. Ther., **17**, 1164-1172

Bhat, R., Dempe, S., Dinsart, C. and Rommelaere, J. (2011) *Enhancement of NK cell antitumor responses using an oncolytic parvovirus* Int. J. Cancer, **128**, 908–919

Brandenburger, A. and Velu, T. (2004) *Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus* J. Gene Med., **6**, S203-S211

Dempe, S., Stroh-Dege, A.Y., Schwarz, E., Rommelaere, J. and Dinsart, C. (2010) *SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-IPV* Int. J. Cancer, **126**, 2914–2927

Enderlin, M., Kleinmann, E.V., Struyf, S., Buracchi, C., Vecchi, A., Kinscherf, R., Kiessling, F., Paschek, S., Sozzani, S., Rommelaere, J., Cornelis, J.J., Van Damme, J. and Dinsart, C. (2009) *TNF- α and the IFN- γ -inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma* Cancer Gene Ther., **16**, 149–160

Hendrie, P.C. and Russell, D.W. (2001) *Homologous gene targeting using an autonomous parvovirus vector* Am. Soc. Gene Ther., 4th Annu. Meeting Abstr. 515

Hendrie, P.C., Hirata, R.K. and Russell, D.W. (2003) *Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus mice* J. Virol., **77**, 13136-13145

Krüger, L., Eskerski, H., Dinsart, C., Cornelis, J., Rommelaere, J., Haberkorn, H. and Kleinschmidt, J.A. (2008) *Augmented transgene expression in transformed cells using a parvoviral hybrid vector* Cancer Gene Ther., **15**, 252-267

Li, J., Werner, E., Hergenahn, M., Poirey, R., Luo, Z., Rommelaere, J. and Jauniaux, J.-C. (2005) *Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1* J. Virol., **79**, 2274-2286

Pozzuto, T., von Kietzell, K., Bock, T., Schmidt-Lucke, C., Poller, W., Zobel, T., Lassner, D., Zeichhardt, H., Weger, S. and Fechner, H. (2011) *Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions* Virology **411**, 50–64

Ruitenbergh, M.J., Eggers, R., Boer, G.J. and Verhaagen, J. (2002) *Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system* *Methods*, **28**, 182-194

Wetzel, K., Struyf, S., Van Damme, J., Kayser, T., Vecchi, A., Sozzani, S., Rommelaere, J., Cornelius, J.J. and Dinsart, C. (2007) *MCP-3 (CCL7) delivered by parvovirus MVMP reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells* *Int. J. Cancer*, **120**, 1364-1371

3.9 Glioma/glioblastoma/medulloblastoma

Enderlin, M., Kleinmann, E.V., Struyf, S., Buracchi, C., Vecchi, A., Kinscherf, R., Kiessling, F., Paschek, S., Sozzani, S., Rommelaere, J., Cornelius, J.J., Van Damme, J. and Dinsart, C. (2009) *TNF- α and the IFN- γ inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma* *Cancer Gene Ther.*, **16**, 149–160

Kiprianova, I., Thomas, N., Ayache, A., Fischer, M., Leuchs, B., Klein, M., Rommelaere, J. and Schlehofer, J.R. (2011) *Regression of glioma in rat models by intranasal application of parvovirus H-1* *Clin. Cancer Res.*, **17**, 5333–5342

Lacroix, J., Schlund, F., Leuchs, B., Adolph, K., Sturm, D., Bender, S., Hielscher, T., Pfister, S.M., Witt, O., Rommelaere, J., Schlehofer, J.R. and Witt, H. (2014) *Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis* *Int. J. Cancer*, **134**, 703–716

Paglino, J.C., Ozduman, K. and van den Pol, A.N. (2012) *LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells* *J. Virol.* 2012, 86(13):7280-7291

3.10 H-PV, large-scale production

Leuchs, B., Roscher, M., Müller, M., Kürschner, K. and Rommelaere, J. (2016) *Standardized large-scale H-1PV production process with efficient quality and quantity monitoring* *J. Virol. Methods*, **229**, 48–59

3.11 Immune system activation

Moehler, M., Sieben, M., Roth, S., Springsguth, F., Leuchs, B., Zeidler, M., Dinsart, C., Rommelaere, J. and Galle, P.R. (2011) *Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1* *BMC Cancer*, **11**: 464

Moralès, O., Richard, A., Martin, N., Mrizak, D., Sénéchal, M., Miroux, C., Pancré, V., Rommelaere, J., Caillet-Fauquet, P., de Launoit, Y. and Delhem, N. (2012) *Activation of a helper and not regulatory human CD4⁺ T cell response by oncolytic H-1 parvovirus* *PLoS One*, **7**: e32197

Raykov, Z., Grekova, S.P., Hörlein, R., Leuchs, B., Giese, T., Giese, N.A., Rommelaere, J., Zawatzky, R. and Daeffler, L. (2013) *TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMP and H-1PV by normal human immune cells* *PLoS One*, **8**: e55086

3.12 Infection/infectivity

Bhat, R. and Rommelaere, J. (2013) *NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells* *BMC Cancer*, **13**: 367

Weiss, N., Stroh-Dege, A., Rommelaere, J., Dinsart, C. and Salomé, N. (2012) *Infectivity of progeny virions H-1PV efficiently stimulates export and protein-coding sequence of parvovirus* *J. Virol.*, **86**, 7554-7564

3.13 Interferon-dependent control

Mattei, L.M., Cotmore, S.F., Tattersall, P. and Iwasaki, A. (2013) *Parvovirus evades interferon-dependent viral control in primary mouse embryonic fibroblasts* *Virology*, **442**, 20–27

3.14 Malignant melanoma

Vollmers, E.M. and Tattersall, P. (2013) *Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses* *Virology*, **446**, 37–48

3.15 Multiple myeloma

Ge, F., Zhang, L., Tao, S.-C., Kitazato, K., Zhang, Z.-P., Zhang, X.-E. and Bi, L.-J. (2011) *Quantitative proteomic analysis of tumor reversion in multiple myeloma cells* *J. Proteome Res.*, **10**, 845-855

3.16 Neo-angiogenesis inhibition

Lavie, M., Struyf, S., Stroh-Dege, A., Rommelaere, J., Van Damme, J. and Dinsart, C. (2013) *Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis* *Virology*, **447**, 221–232

3.17 Non-structural proteins

Weiss, N., Stroh-Dege, A., Rommelaere, J., Dinsart, C. and Salomé, N. (2012) *Infectivity of progeny virions H-1PV efficiently stimulates export and protein-coding sequence of parvovirus* *J. Virol.*, **86**, 7554-7564

Mihaylov, I.S., Cotmore, S.F. and Tattersall, P. (2014) *Complementation for an essential ancillary non-structural protein function across parvovirus genera* Virology, **468-470**, 226–237

3.18 Oncolytic capacity

Alkassar, M., Gärtner, B., Roemer, K., Graesser, F., Rommelaere, J., Kaestner, L., Haeckel, I. and Graf, N. (2011) *The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo* J Neurooncol., **104**, 715–727

El-Andaloussi, N., Bonifati, S., Kaufmann, J.K., Mailly, L., Daeffler, L., Deryckère, F., Nettelbeck, D.M., Rommelaere, J. and Marchini, A. (2012) *Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential* J. Virol., **86**, 10418-10431

Lacroix, J., Schlund, F., Leuchs, B., Adolph, K., Sturm, D., Bender, S., Hielscher, T., Pfister, S.M., Witt, O., Rommelaere, J., Schlehofer, J.R. and Witt, H. (2014) *Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis* Int. J. Cancer, **134**, 703–716

Moehler, M., Sieben, M., Roth, S., Springsguth, F., Leuchs, B., Zeidler, M., Dinsart, C., Rommelaere, J. and Galle, P.R. (2011) *Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1* BMC Cancer, **11**: 464

Moralès, O., Richard, A., Martin, N., Mrizak, D., Sénéchal, M., Miroux, C., Pancré, V., Rommelaere, J., Caillet-Fauquet, P., de Launoit, Y. and Delhem, N. (2012) *Activation of a helper and not regulatory human CD4⁺ T cell response by oncolytic H-1 parvovirus* PLoS One, **7**: e32197

Sieben, M., Schafer, P., Dinsart, C., Galle, P.R. and Moehler, M. (2013) *Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1* Int. J. Cancer, **132**, 2548–2556

Titze, M.I., Frank, J., Ehrhardt, M., Smola, S., Graf, N. and Lehr, T. (2017) *A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth* Eur. J. Pharmaceut. Sci., **97**, 38–46

3.19 Pancreatic cancer

Angelova, A.L., Grekova, S.P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., Aprahamian, M., Bour, G., Rüffer, S., Cziepluch, C., Daeffler, L., Rommelaere, J., Werner, J., Raykov, Z. and Giese, N.A. (2014) *Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer* J. Virol., **88**, 5263–5276

Dempe, S., Lavie, M., Struyf, S., Bhat, R., Verbeke, H., Paschek, S., Berghmans, N., Geibig, R., Rommelaere, J., Van Damme, J. and Dinsart, C. (2012) *Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment* Cancer Immunol. Immunother., **61**, 2113–2123

3.20 Recombinant production

Brown, C.S., DiSumma, F.M., Rommelaere, J., Dege, A.Y., Cornelis, J.J., Dinsart, C. and Spaan, W.J.M. (2002) *Production of recombinant H1 parvovirus stocks devoid of replication-competent viruses* Hum. Gene Ther., **13**, 2135-2145

3.21 Tumour reversion/therapy

Ge, F., Zhang, L., Tao, S-C., Kitazato, K., Zhang, Z-P., Zhang, X-E. and Bi, L-J. (2011) *Quantitative proteomic analysis of tumor reversion in multiple myeloma cells* J. Proteome Res., **10**, 845-855

Réjiba, S., Bigand, C., Parmentier, C., Masmoudi, A. and Hajri, A. (2013) *Oncosuppressive suicide gene virotherapy “PVH1-γCD/5-FC” for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement* PLoS One, **8**: e70594

Sieben, M., Schafer, P., Dinsart, C., Galle, P.R. and Moehler, M. (2013) *Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1* Int. J. Cancer, **132**, 2548–2556

Mini-Review MV08: 3rd edition, February 2018

Alere Technologies AS

Axis-Shield Density Gradient Media
is a brand of Alere Technologies AS